Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Poor oral health (periodontal disease) impacts nearly 51% of Indians
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
The company will also share results in two additional posters for deuruxolitinib
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated
